A systematic review of the effectiveness of adalimumab

112
Health economics
TABLE 68 Sensitivity analyses: TNF inhibitors in last place
Scenario Adal – Base Etan – Base Adal+MTX – Etan+MTX – Infl+MTX –
Base Base Base
Base case 40,100 23,700 29,700 23,800 37,900
No HAQ progression on TNF inhibitors 27,100 18,100 22,100 18,000 25,700
Slow HAQ progression on all DMARDs 39,500 24,400 30,500 24,900 37,600
Slow HAQ progression on all treatments 64,100 33,400 43,000 34,000 60,500
Fast HAQ progression on all treatments 58,300 30,300 39,400 30,000 53,300
No effect of HAQ on mortality 40,100 23,200 30,000 23,400 38,600
Mortality ratio 2.73 per unit HAQ 37,500 23,000 29,500 23,100 34,900
Effectiveness of conventional DMARDs
down 50%
39,500 23,900 29,800 23,800 37,400
Effectiveness of conventional DMARDs
up 50%
38,900 23,600 29,400 23,900 38,200
Survival times on conventional DMARDs
down 50%
38,500 23,700 28,900 24,000 37,700
Survival times on conventional DMARDs
up 50%
39,500 23,700 30,300 23,600 38,800
Survival times on TNF inhibitors down 50% 43,800 24,700 32,800 25,700 43,500
Survival times on TNF inhibitors up 50% 37,200 22,800 28,900 23,000 36,600
Review at 12 weeks 39,700 23,300 29,400 23,900 37,800
Short-term quitters on TNF inhibitors
down 50%
40,800 23,900 30,200 24,100 38,400
Short-term quitters on TNF inhibitors
up 50%
39,000 23,400 29,400 23,700 37,400
Short-term quitters on conventional
DMARDs down 50%
39,300 23,500 29,500 23,800 37,400
Short-term quitters on conventional
DMARDs up 50%
38,300 23,900 29,800 24,000 36,500
Include offset costs 38,400 22,300 27,900 22,400 36,100